Tag: Eli Lilly October 26, 2022 New strategy shows potential to block nerve loss in neurodegenerative diseasesResearch into how key molecule triggers axon death may lead to new therapies.News Release October 20, 2020 Startup company founded by Washington University scientists acquired by Eli LillyDrugmaker purchases Disarm Therapeutics to develop treatments for neurodegenerative diseases.Medical Campus & Community February 10, 2020 Investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s, initial analysis indicatesTop-line data reported from international trial.News Release Posts navigation
